Analyst Research

Report Title Price
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aegerion Pharmaceuticals Inc Raises FY 2013 Revenue Guidance


Wednesday, 30 Oct 2013 07:00am EDT 

Aegerion Pharmaceuticals Inc raised its fiscal 2013 revenue guidance for net product sales to $45 to $50 million, from the previous range of $30 to $35 million. The upward revision primarily reflects the Company's results and insights to date with respect to the launch of JUXTAPID in the U.S. Aegerion continues to expect total operating expenses, excluding stock-based compensation expense, to be between $75 and $85 million in 2013. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $40 million for fiscal 2013. 

Latest Key Developments in Pharmaceuticals

Company Quote

28.47
-0.24 -0.84%
11 Jul 2014